Kush Naker

Employment

Employment history is unavailable.

Education

• London School of Hygiene and Tropical Medicine Tropical Medicine and International Health MSc
  2016 - 2017

Projects & Funding

Projects & funding information is unavailable.

Publications (9)

• Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised …
  The Lancet Infectious Diseases 2022 DOI: 10.1016/s1473-3099(22)00271-7
  +Save
• Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults
  Journal of Infection 2022 DOI: 10.1016/j.jinf.2022.06.009
  +Save
• Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial
  The Lancet 2022 DOI: 10.1016/s0140-6736(21)02718-5
  +Save
• Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
  The Lancet 2021 DOI: 10.1016/s0140-6736(21)02717-3
  +Save
• Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
  The Lancet 2021 DOI: 10.1016/s0140-6736(21)01694-9
  +Save
• Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
  The Lancet 2021 DOI: 10.1016/s0140-6736(21)00628-0
  +Save
• Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
  The Lancet 2021 DOI: 10.1016/s0140-6736(21)00432-3
  +Save
• Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
  The Lancet 2021 DOI: 10.1016/s0140-6736(20)32661-1
  +Save
• An e-registry for household contacts exposed to multidrug resistant TB in Mongolia
  BMC Medical Informatics and Decision Making 2020 DOI: 10.1186/s12911-020-01204-z
  +Save